Avadel pharmaceuticals provides corporate update and reports first quarter 2021 financial results

Dublin, ireland, may 10, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the first quarter ended march 31, 2021.
AVDL Ratings Summary
AVDL Quant Ranking